Vaccine News and Research

Latest Vaccine News and Research

Future attempts to reduce Covid-19 spread should focus on tackling airborne transmission

Any future attempts to reduce the spread of covid-19 should be focused on tackling close airborne transmission of the virus which is considered to be the primary route for its circulation, according to experts in an editorial published in The BMJ.

15 Apr 2021

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

A new study by researchers in Jerusalem indicates that while specific antibodies to the virus are present in both serum and ovarian follicles following infection or vaccination, there is no apparent adverse effect on follicular function as a result.

15 Apr 2021

Survey data shows strong readiness among young people for COVID-19 vaccination

As older teens and young adults become eligible for COVID-19 vaccination across the country, and younger teens await their turn, new survey data suggest a strong readiness that has grown since fall.

15 Apr 2021

Study shows why social media users are more hesitant about getting vaccinated

New research has found that the most reliable indicators of willingness to be vaccinated against SARS-CoV-2, the virus that causes COVID-19, are rejection of conspiracy suspicions about COVID-19 and a positive attitude towards vaccines in general.

15 Apr 2021

Self-assembling nanofibers can help limit damage caused by inflammatory diseases

Biomedical engineers at Duke University have developed a self-assembling nanomaterial that can help limit damage caused by inflammatory diseases by activating key cells in the immune system.

15 Apr 2021

New research could help solve major challenge in the deployment of COVID-19 vaccines

New research by University of Texas at Dallas scientists could help solve a major challenge in the deployment of certain COVID-19 vaccines worldwide -- the need for the vaccines to be kept at below-freezing temperatures during transport and storage.

15 Apr 2021

Speed of vaccination is key to reducing COVID-19 spread, says study

Mathematical modeling of the effects of vaccine efficacy and the speed of vaccination show that a lower efficacy vaccine may curb disease transmission similar to that of a higher efficacy vaccine if the speed of immunization is high.

15 Apr 2021

Ebola virus's key protein uses molecular triggers in the human cell to change shape

The human genome contains the instructions to make tens of thousands of proteins. Each protein folds into a precise shape - and biologists are taught that defined shape dictates the protein's destined function.

15 Apr 2021

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

A new study published ahead of print in the Clinical Chemistry and Laboratory Medicine (CCLM) journal reports the production of a robust immune response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using the Pfizer-BioNTech BNT162b2 vaccine. The increase in humoral immunity includes elevated Immunoglobulin G (IgG) and Immunoglobulin A (IgA) levels after the second mRNA dose.

14 Apr 2021

Phase 3 trial finds corticosteroid inhaler speeds recovery time in COVID-19 patients

The corticosteroid budesonide shows promise in treating patients with mild COVID-19 infection. Interim analysis of the phase 3 PRINCIPLE clinical trial was posted to the medRxiv preprint server. Researchers found a 3-day faster recovery of COVID-19 symptoms in people at high risk for severe side effects administered a budesonide inhaler. There was also a 2.1% reduction in hospitalization and death.

14 Apr 2021

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

Researchers in the United States have conducted a pre-clinical study demonstrating the efficacy of two updated versions of the Moderna mRNA-1273 vaccine against variants of severe acute respiratory syndrome coronavirus 2 – the agent that causes coronavirus disease 2019 (COVID-19).

14 Apr 2021

SARS-CoV-2 mutations impact T-cell recognition of virus

A new research paper posted to the bioRxiv preprint server deals with the impact of these mutations on adaptive cellular immunity.

14 Apr 2021

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

As newer vaccines are being developed to combat the ongoing pandemic of coronavirus disease 2019 (COVID-19), targeting the pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new preprint research paper posted to the bioRxiv server describes a new subunit nanovaccine that appears to have robust immunogenicity and neutralizing activity.

14 Apr 2021

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

A new research paper posted to the medRxiv* preprint server describes the changes in genomic sequence observed during the course of infection in a patient on the drug tacrolimus, along with steroids, both potent immunosuppressants, and who also received convalescent plasma treatment. These mutations were observed to occur within three weeks from infection.

14 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

The study, published in The Lancet, demonstrates that there is no evidence of a link between severe illness and death and lineage when comparing the B.1.1.7 lineage and other variants.

14 Apr 2021

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Recently, researchers from the U.S. reviewed electronic health records of SARS-CoV-2 patients at a medical center that started mAb infusions in January 2021 with the support of the National Disaster Medical System, part of the U.S. Department of Health and Human Services. The study is published on the preprint server, medRxiv.

14 Apr 2021

Study of antiviral nutraceutical phenolics against SARS-CoV-2 main protease

To address this issue, a team of researchers led by Professor Mohamed El Raey of the National Research Centre, Dokki, Cairo, Egypt, looked at phytopharmaceuticals and nutraceuticals as potential antivirals against SARS-CoV-2.

13 Apr 2021

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Researchers in the United States have identified 95 high-frequency mutations in the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that threaten to compromise the efficacy of current and future vaccines and antibody therapies for coronavirus disease 2019 (COVID-19).

13 Apr 2021

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently neutralize variants of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Apr 2021

Vaccine News and Research

Latest Vaccine News and Research

Future attempts to reduce Covid-19 spread should focus on tackling airborne transmission

Ovarian follicular function unaffected by SARS-CoV-2 infection or Pfizer vaccine, study finds

Survey data shows strong readiness among young people for COVID-19 vaccination

Study shows why social media users are more hesitant about getting vaccinated

Self-assembling nanofibers can help limit damage caused by inflammatory diseases

New research could help solve major challenge in the deployment of COVID-19 vaccines

Speed of vaccination is key to reducing COVID-19 spread, says study

Ebola virus's key protein uses molecular triggers in the human cell to change shape

Evidence of sustained immune responses weeks after Pfizer-BioNTech BNT162b2 vaccination

Phase 3 trial finds corticosteroid inhaler speeds recovery time in COVID-19 patients

Updated Moderna vaccines neutralize South African SARS-CoV-2 variant in mice

SARS-CoV-2 mutations impact T-cell recognition of virus

A new polymersome-based SARS-CoV-2 nanovaccine elicits robust immunity

Study demonstrates that the main creators of SARS-CoV-2 mutations are vaccine-suppressed

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

Risk of E.R. visit or hospitalization 82% lower in mAbs-treated SARS-CoV-2 patients: Study

Study of antiviral nutraceutical phenolics against SARS-CoV-2 main protease

A host of mutations could compromise COVID-19 vaccines and antibody therapies

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in